• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:熊晗晖,冯端浩,赵冠人,李艳丽,孔华丽.莫西沙星治疗难治复治多耐药肺结核的系统评价[J].中国现代应用药学,2010,27(7):656-660.
.Moxifloxacin for Refractory, Recurrent, Multi-Drug Resistant Pulmonary Tuberculosis: A Systematic Review[J].Chin J Mod Appl Pharm(中国现代应用药学),2010,27(7):656-660.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2275次   下载 2304 本文二维码信息
码上扫一扫!
分享到: 微信 更多
莫西沙星治疗难治复治多耐药肺结核的系统评价
熊晗晖,冯端浩,赵冠人,李艳丽,孔华丽
作者单位
摘要:
目的 系统评价莫西沙星联合抗结核药物治疗复治肺结核的疗效与安全性。方法 检索Medline(1950—2009)、外文全文生物医学期刊(FJIS,1995—2008)、中国医院数字图书馆(CNKI,1994—2008)、中国生物医学文献数据库(CBMdisc,1977—2008)、WHO EML等数据库和网站中所有莫西沙星治疗难治复治多耐药肺结核随机对照临床试验,按照《药品文献评价指导原则》同时采用Cochrane协作网提供的RevMan 4.2.10软件分析数据。结果 最终纳入7个RCT。Meta分析结果显示,莫西沙星治疗组与对照组相比,痰菌转阴率[RR=1.11,95%CI(1.03,1.19)],临床有效率[RR=1.14,95%CI(1.04,1.25)]的差异均有统计学意义。结论 现有证据表明,莫西沙星用于难治、复治、多耐药肺结核治疗,有助于痰菌转阴。
关键词:  莫西沙星  难治  复治  多耐药  肺结核  系统分析
DOI:
分类号:
基金项目:
Moxifloxacin for Refractory, Recurrent, Multi-Drug Resistant Pulmonary Tuberculosis: A Systematic Review
XIONG Hanhui  FENG Duanhao  ZHAO Guanren  LI Yanli  KONG Huali
Abstract:
OBJECTIVE To assess the effectiveness and security of moxifloxacin for refractory, recurrent, multi-drug resistant pulmonary tuberculosis. METHODS To search he Medline(1950-2009), FJIS(1995-2008), CNKI(1994-2008), CBMdisc(1977-2008) , WHO EML to collect randomized controlled trails (RCTs) which moxifloxacin was uesd for refractory, recurrent, multi-drug resistant pulmonary tuberculosis. RESULTS The data included 7 RCTs was analyzed by using the Cochrane Collaboration’s RevMan 4.2.10 software. Compared with control group, moxifloxacin was more effective in sputum negative conversion rate [RR=1.11, 95%CI(1.03, 1.19)] and clinical efficacy rate[RR=1.14, 95%CI(1.04, 1.25)]. CONCLUSION Moxifloxacin is useful for sputum negative conversion in patients with refractory, recurrent, multi-drug resistant pulmonary tuberculosis.
Key words:  moxifloxacin  refractory  recurrent  multi-drug resistant  pulmonary tuberculosis  systematic review
扫一扫关注本刊微信